CytoDyn will host a webcast on April 6th to provide a full update on its business

Vancouver

VANCOUVER, Wash., April 1, 2021 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix ™ (leronlimab-PRO 140)) , a CCR5 antagonist with potential for multiple therapeutic indications, announced today that Dr. Nader Pourhassan, President and Chief Executive Officer, Dr. Scott Kelly, Chairman and Chief Medical Officer, Dr. Christopher Recknor, Chief Operating Officer and Mahboob Rahman, MD, Ph.D., Chief Scientific Officer, will webcast the investment community on Tuesday, April 6, 2021.

Management will keep its shareholders fully informed of the company’s activities, including recent COVID-19 initiatives and information on its active studies on COVID-19, NASH and cancer.

Management will have approximately 60 minutes to answer questions posed online by analysts and investors.

Date: Tuesday, April 6, 2021 Time: 1:00 p.m. PT / 4:00 p.m. ET Dial-in: None. Ask:

Questions can be submitted online prior to the webcast to

Questions can be submitted during the webcast using the webcast link below.

This is a “listen only” webcast that can be accessed via the CytoDyn corporate website at www.cytodyn.com in the Investors / IR Calendar section and is archived for 30 days. Attendees are encouraged to go to the website 15 minutes before the webcast begins to register, download, and install the required software. Please note that the website below is only operational approx. 60 minutes before the start of the webcast, which you can access via the following link:

The replay will be available approximately 60 minutes after the webcast closes and can be accessed through the link above until May 6, 2021.